Concepedia

Author

Jennifer M. Specht

University of WashingtonORCID

Also Known As

Dodelzon, Katerina, Foluso Ademuyiwa, J M Specht, J Specht, J. M. Specht, J. SPECHT, J. Specht, J.M. Specht, Jennifer M Specht, Jennifer M. Specht

246

Publications

4K

Citations

32

H-Index

64

Concepts

All Affiliations

University of WashingtonFred Hutch Cancer CenterSeattle Cancer Care AllianceUniversity of PittsburghDana-Farber Cancer Institute
JM

About

Jennifer M. Specht is an author at University of Washington specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

25

1.8K

2

Health Sciences

4

4

242

3

Engineering

1

1

45

4

Nursing

1

1

10

5

Anesthesia

1

1

19

Jennifer M. Specht

×

53

Publications

3.5K

Citations

30

H-Index

YearCitations

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber,

Annals of Oncology

2022

404

Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade

Shivani Srivastava, Scott N. Furlan, Carla A. Jaeger-Ruckstuhl,

Cancer Cell

2020

316

Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases

Jennifer M. Specht, Gang Wang, My T.,

The Journal of Experimental Medicine

1997

306

Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

Joyce O’Shaughnessy, Lee Schwartzberg, Michael Danso,

Journal of Clinical Oncology

2014

299

Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

Lisa K. Dunnwald, Julie R. Gralow, Georgiana K. Ellis,

Journal of Clinical Oncology

2008

156

Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Hannah M. Linden, Brenda F. Kurland, Lanell M. Peterson,

Clinical Cancer Research

2011

140

PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake

Lisa K. Dunnwald, Robert K. Doot, Jennifer M. Specht,

Clinical Cancer Research

2011

115

Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)

Jennifer M. Specht, Stephen L. Tam, Brenda F. Kurland,

Breast Cancer Research and Treatment

2007

108

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Pamela N. Münster, Rahul Aggarwal, David S. Hong,

Clinical Cancer Research

2015

108

A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

Lanell M. Peterson, Brenda F. Kurland, Erin K. Schubert,

Molecular Imaging and Biology

2013

103

Page 1